Global Down-Regulation of Gene Expression in the Brain Using RNA Interference, with Emphasis on Monoamine Transporters and GPCRs: Implications for Target Characterization in Psychiatric and Neurological Disorders
- 1 January 2006
- journal article
- Published by Taylor & Francis in Journal of Receptors and Signal Transduction
- Vol. 26 (5-6) , 527-547
- https://doi.org/10.1080/10799890600929663
Abstract
RNA interference (RNAi) is a natural mechanism for regulating gene expression, which exists in plants, invertebrates, and mammals. We investigated whether non-viral infusion of short interfering RNA (siRNA) by the intracerebroventricular route would enable a sequence-specific gene knockdown in the mouse brain and whether the knockdown translates into disease-relevant behavioral changes. Initially, we targeted enhanced green fluorescent protein (EGFP) in mice overexpressing EGFP. A selective knockdown of both EGFP protein and mRNA was observed throughout the brain, with lesser down-regulation in regions distal to the infusion site. We then targeted endogenous genes, encoding the dopamine (DAT) and serotonin transporters (SERT). DAT-siRNA infusion in adult mice produced a significant down-regulation of DAT mRNA and protein and elicited hyperlocomotion similar, but delayed, to that produced on infusion of GBR-12909, a potent and selective DAT inhibitor. Similarly, SERT-siRNA infusion resulted in significant knockdown of SERT mRNA and protein and elicited reduced immobility in the forced swim test similar to that obtained on infusion of citalopram, a very selective and potent SSRI. Application of this non-viral RNAi approach may accelerate target validation for neuropsychiatric disorders that involve a complex interplay of gene(s) from various brain regions.Keywords
This publication has 38 references indexed in Scilit:
- RNAI AS AN EXPERIMENTAL AND THERAPEUTIC TOOL TO STUDY AND REGULATE PHYSIOLOGICAL AND DISEASE PROCESSESAnnual Review of Physiology, 2005
- An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu,Zn superoxide dismutaseJournal of Neurochemistry, 2005
- Therapeutic Potential of RNA InterferenceNew England Journal of Medicine, 2004
- Intravenous RNA Interference Gene Therapy Targeting the Human Epidermal Growth Factor Receptor Prolongs Survival in Intracranial Brain CancerClinical Cancer Research, 2004
- Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cellsProceedings of the National Academy of Sciences, 2004
- RNAi Therapeutics: How Likely, How Soon?PLoS Biology, 2004
- Efficient and specific down-regulation of prion protein expression by RNAiBiochemical and Biophysical Research Communications, 2003
- Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA virusesBMC Microbiology, 2001
- Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegansNature, 1998
- Reviews : Antisense oligonucleotides in psychopharmacology and behaviour: promises and pitfallsJournal of Psychopharmacology, 1997